Acadia Pharmaceuticals Inc. (ACAD)
NASDAQ
Closed
Aug 24, 2026
Day's Range
29.1552 wk Range
19.69Overview - ACAD - Acadia Pharmaceuticals Inc.
Key Statistics
Valuation
Enterprise Value
4.20B
P/E (Trailing)
‪13.22‬
P/E (Forward)
‪33.20‬
PEG Ratio
‪1.05‬
Price / Sales (TTM)
‪4.46‬
Price / Book
‪3.88‬
EV / EBITDA
‪42.69‬
Profitability
Gross Margin
‪90.80%‬
Profit Margin
‪33.41%‬
Operating Margin
‪12.28%‬
Return on Assets
‪3.63%‬
Return on Equity
‪35.74%‬
Ownership
Shares Outstanding
172.13M
Float
128.35M
Short % of Shares Outstanding
‪9.92%‬
Held by Insiders
‪0.32%‬
Held by Institutions
‪99.76%‬
Price stats
Beta
‪0.84‬
50-Day Avg
‪25.86‬
200-Day Avg
‪24.16‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
21 analysts
Average price target
‪$ 33.85‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ACAD - Acadia Pharmaceuticals Inc.
Peers - ACAD - Acadia Pharmaceuticals Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ACADNASDAQAcadia Pharmaceuticals Inc.5.08BMarket Cap+14.17%52-week change13.16P/E (Trailing)‪33.41%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt65.04BMarket Cap+34.86%52-week change39.69P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc31.60BMarket Cap-87.81%52-week change41.15P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE29.28BMarket Cap+9.87%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.61BMarket Cap+23.98%52-week change19.38P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.93BMarket Cap+41.98%52-week change-21.56P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.91BMarket Cap+12.29%52-week change180.27P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ACAD - Acadia Pharmaceuticals Inc.
About
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological disorders and rare diseases. The company’s primary purpose is to address conditions with significant unmet medical needs, particularly in central nervous system indications. Acadia’s…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
